Invitae reported full-year revenues of $279.6 million in 2020, up from $216.8 million in the prior year. Its net loss widened $608.9 million last year, compared with $242 million in 2019.
While genetic information can be a powerful tool in combating various maladies, George said high costs have historically limited its availability and, by extension, the impact it can have. However, he said, recent gene-sequencing innovations have laid the groundwork for more accessibility. He likened it to semiconductor improvements helping kickstart the computing and networking industry"That has enabled ... application providers like us ...
George, who has a Ph.D. in molecular genetics, said Invitae hopes to get its tests to the point where patients and doctors can use them proactively in large numbers. That way, even if the cost of each test is cheaper, Invitae will have the scale to generate enough operating cash to thrive as a company, he said.
"The massive importance and central importance of genetic information in health care is about to — I'm certain in the next five to 10 years — is about to come front and center as an ability to get the right therapy earlier to individuals that can benefit, identify people at risk, and put in place monitoring and prevention modalities to certainly delay, if not even prevent, the onset of disease and generally provide a core understanding of risk that runs in families," he added.
Ark Invest has positions in a range of companies working on medical innovation beyond Invitae. Wood's firm has an ETF dedicated to it, called the Genomic Revolution ETF . As of Thursday, it includes
세계평화 질서유지 유대인 격리조치 해야합니다. 널리 인간세계(人間世界)를 이롭게 한다.
이르시기를 나의 기름 부은 자를 손대지말며TheFridayVigil 2021.03.13
I guess she can speak, but Elon can't... 😑
Who’s wishing they were on board now aye Cathie?🚀👍
Tell her its $KOPN.........
It's boring to sit at home alone, looking for someone to spend time with